Emmessar biotech & Nutrition Limited has submitted its quarterly compliance certificate to the Bombay Stock Exchange, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing demonstrates the company's adherence to mandatory disclosure norms for listed entities regarding dematerialisation processes.

Regulatory Compliance Filing

The company filed the certificate on 8th April, 2026, addressing compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026. The submission was made to the Listing Department of Bombay Stock Exchange Limited, where the company trades under stock code 524768.

Registrar Confirmation

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Pvt. Ltd.), serving as the company's Registrar and Share Transfer Agent. The registrar provided confirmation on 3rd April, 2026, which was received by Emmessar Biotech & Nutrition Limited on 4th April, 2026 via email.

MUFG Intime India confirmed that securities received from depository participants for dematerialisation during Q4FY26 were properly processed and confirmed to the depositories. The registrar verified that all security certificates received for dematerialisation were confirmed or rejected within prescribed timelines.

Dematerialisation Process Compliance

The certificate confirms several key compliance aspects of the dematerialisation process:

• Securities received from depository participants were confirmed (accepted/rejected) to depositories
• Security certificates have been listed on stock exchanges where earlier issued securities are listed
• Received security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within prescribed timelines

Corporate Information

Emmessar Biotech & Nutrition Limited operates from its registered office and factory at Plot No. T-3/2, MIDC Area, Taloja – 410208, Dist. Raigad, Maharashtra. The company maintains its corporate office at 29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai. Priyanka Sharma serves as the Company Secretary and Compliance Officer, signing the regulatory filing on behalf of the company.

Emmessar biotech & Nutrition Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating improved profitability compared to the previous year. The company's Board of Directors approved these results at their meeting held on February 11, 2026.

Financial Performance Overview

The company reported strong financial performance for the third quarter of FY26, with significant improvement in net profitability year-over-year.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Emmessar Biotech & Nutrition Limited maintained steady performance across key financial metrics.

Segment-wise Revenue Analysis

The company operates through multiple business segments, with rent on leasehold land being the primary revenue contributor.

Q3 FY26 Segment Performance:

• Healthcare: ₹9.34 lakhs revenue, ₹5.80 lakhs profit before tax
• Rent on leasehold land: ₹41.33 lakhs revenue, ₹41.10 lakhs profit before tax
• Others: ₹7.65 lakhs revenue, ₹7.65 lakhs profit before tax

Expense Management

Total expenses for Q3 FY26 were ₹45.47 lakhs compared to ₹39.94 lakhs in Q3 FY25. Key expense components included employee benefit expenses of ₹32.99 lakhs and other expenses of ₹6.38 lakhs. The company maintained disciplined cost management across operational categories.

Regulatory Compliance

The financial results have been prepared in accordance with Indian Accounting Standard 34 and comply with Regulation 33 of SEBI Listing Regulations. The results were reviewed by the Audit Committee and subjected to limited review by statutory auditors V. Nagarajan & Co. The company reported no investor complaints during the quarter ended December 31, 2025.